A Randomized, Double-Blind, Dose-Ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate.

Trial Profile

A Randomized, Double-Blind, Dose-Ranging Trial of CNTO 148 Subcutaneous Injection Compared With Placebo in Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2012

At a glance

  • Drugs Golimumab (Primary) ; Infliximab
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Aug 2012 Trial phase changed from III to II as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Results correlating efficacy and inflammatory biomarker levels have been reported in the Journal of .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top